NuVasive price target raised to $22 from $19 at RW Baird Baird raised its price target on NuVasive following solid Q4 results. The firm cited reasons to expect higher revenue growth on better than expected leverage opportunities. Baird likes the risk/reward and maintains its Outperform rating.
News For NUVA From The Last 14 Days
Check below for free stories on NUVA the last two weeks.